A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
BeOne Medicines
National Institutes of Health Clinical Center (CC)
Mayo Clinic
St. Jude Children's Research Hospital
Regeneron Pharmaceuticals
Wake Forest University Health Sciences
University of Alabama at Birmingham
Regeneron Pharmaceuticals
Roswell Park Cancer Institute
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
Beijing Biotech
Weill Medical College of Cornell University
AstraZeneca
Hackensack Meridian Health
Hackensack Meridian Health
Hoffmann-La Roche
The Methodist Hospital Research Institute
ModernaTX, Inc.
Nanjing IASO Biotechnology Co., Ltd.
Hackensack Meridian Health
Fred Hutchinson Cancer Center
Alliance for Clinical Trials in Oncology
Sumitomo Pharma America, Inc.
Alexion Pharmaceuticals, Inc.
Hackensack Meridian Health
Hoosier Cancer Research Network
Celgene
Regeneron Pharmaceuticals
Ciusss de L'Est de l'Île de Montréal
M.D. Anderson Cancer Center
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Janssen Research & Development, LLC
M.D. Anderson Cancer Center
Brigham and Women's Hospital
Hangzhou Sumgen Biotech Co., Ltd.
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
Mayo Clinic
Gracell Biotechnologies (Shanghai) Co., Ltd.
Fortvita Biologics (USA)Inc.
Dana-Farber Cancer Institute
AbbVie
Hebei Senlang Biotechnology Inc., Ltd.
Hackensack Meridian Health
M.D. Anderson Cancer Center
Essen Biotech
University of Texas Southwestern Medical Center
AbbVie
Memorial Sloan Kettering Cancer Center